NCT00430170View on ClinicalTrials.gov

Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2007

Study Completion Date

April 30, 2007

Conditions
Cardiovascular DiseaseIschemia-Reperfusion Injury
Interventions
DRUG

Dipyridamole

Dipyridamole 2x200mg 7day per os

DRUG

caffeine

caffeine 4mg/kg iv

Trial Locations (1)

6500hb

Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT00430170 - Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? | Biotech Hunter | Biotech Hunter